@article{fdi:010046017,
  title = {{B}iological measure of compliance to {A}rtesunate plus {A}modiaquine association : interest in a {M}ono-{D}esethyl-{A}modiaquine blood assay ?},
  author = {{S}arrassat, {S}ophie and {S}akho, {M}. and {L}e {H}esran, {J}ean-{Y}ves},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he deployment of {A}rtemisinin-based {C}ombination {T}herapy for treating uncomplicated malaria poses problems in the patient compliance to these new treatments. {T}he aim of our study was to investigate the relationship between compliance to 3 days treatment with {A}rtesunate plus {A}modiaquine ({AS}+{AQ}) and the {M}ono-{D}esethyl-{A}modiaquine ({MDA}) blood concentration on the fourth day. {A} reference scale of mean {MDA} blood concentrations was constructed in 40 healthy adults. {E}ach concentration corresponded to the {MDA} level on day 3 in a subject having one of the seven compliance degrees defined by the number and sequence of drug intakes from day 0 to day 2: one single dose on day 0, day 1 or day 2; two single doses separated by 24 h, on day 0 and day 1 or on day 1 and day 2; two single doses separated by 48 h, on day 0 and day 2; three single doses, on day 0, day 1 and day 2. {MDA} was assayed in whole blood samples by {HPLC}. {N}on-parametric {M}ann and {W}hitney {U} tests were used for the comparison of two means. {O}ur results demonstrated no clear relationship between the mean {MDA} blood concentrations on day 3 and compliance degrees, according to neither the number nor the sequence of doses taken. {I}n particular, even though the differences were not significant, the mean concentration after three doses, expected to be the maximum, was unexpectedly lower than after two doses, on day 0 and day 1 or on day 1 and day 2. {T}he high inter-individual variability of {MDA} concentrations attributed to the different rates of hepatic metabolism of each individual appears to have a greater effect on {MDA} levels than the number or timing of doses. {T}herefore, it seems that the role of a {MDA} blood assay is limited in use to discerning if none or one or more doses have been taken. {A} {MDA} assay do not allow to measure the compliance degree of one patient to {AS} + {AQ} association. {P}resently, interview and pill count following treatment seem to be the only tools available that may permit differentiation between degrees of compliance.},
  keywords = {{A}rtesunate plus {A}modiaquine ; {C}ompliance ; {B}lood assay},
  booktitle = {},
  journal = {{A}cta {T}ropica},
  volume = {110},
  numero = {1},
  pages = {1--6},
  ISSN = {0001-706{X}},
  year = {2009},
  DOI = {10.1016/j.actatropica.2008.11.001},
  URL = {https://www.documentation.ird.fr/hor/fdi:010046017},
}